First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial.

Management of advanced B cell malignancies refractory to standard chemotherapy is challenging with sub-optimal results. Recent clinical reports of durable, objective responses from adoptive transfer of anti-CD19 chimeric antigen receptor (CAR) T cells have accentuated the potential of this therapy. Here we report the preliminary results of an on-going Phase I clinical trial at our Institution.